10201603055W

Text of the abstract

The present invention describes combination treatment comprising a PD-1 axis binding antagonist, chemotherapy and optionally a VEGF antagonist and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer. In a particular embodiment, the combination treatment comprises (a) a PD-1 binding antagonist, a PD-L1 binding antagonist or a PD-L2 binding antagonist and (b) oxaliplatin, leucovorin and 5-FU.